Formulated Products, Institute of Chemical and Engineering Sciences, A*STAR (Agency for Science, Technology and Research), 1 Pesek Road, Jurong Island, 627833, Singapore.
Eur J Pharm Biopharm. 2020 Apr;149:95-104. doi: 10.1016/j.ejpb.2020.01.021. Epub 2020 Feb 5.
Renaissance of cocrystals as alternative solid forms for fine-tuning physicochemical properties of active pharmaceutical ingredients (APIs) has paved way for development of marketable cocrystals. The current literature reveals established strategies for the design, synthesis and characterization of cocrystals. However, barring a few isolated case studies, strategies for development of cocrystal formulations have been underdeveloped. Herein we report topical formulations of an antioxidant, ferulic acid (FA), which contain the active in its cocrystal form. Cocrystals of FA with the coformers relevant to skin care such as urea, nicotinamide (NA) and isonicotinamide (INA) have been prepared and oleogel formulations of these have been developed. The cocrystal with urea and an anhydrous cocrystal with INA have been identified for the first time in this study. The novel cocrystals were structurally characterized by single crystal X-ray diffraction. Solubility and stability studies have revealed higher solubility of the cocrystals with NA and INA than the parent active and greater stability of FA in formulations that contained the cocrystals with INA and urea than the corresponding formulations containing physical mixtures or parent active. In vitro membrane permeation tests have ascertained sustained release profile of active from the formulation that contained the FA•INA cocrystal. The higher solubility, greater stability and sustained active release profile of the FA•INA cocrystal formulation make it a promising topical formulation of FA.
作为精细调整活性药物成分(API)物理化学性质的替代固体形式,共晶的复兴为可销售的共晶的发展铺平了道路。目前的文献揭示了共晶的设计、合成和表征的既定策略。然而,除了少数孤立的案例研究外,共晶制剂的开发策略还不够发达。本文报道了抗氧化剂阿魏酸(FA)的局部制剂,其中包含其共晶形式的活性成分。已经制备了 FA 与皮肤护理相关的共晶形成剂(如尿素、烟酰胺(NA)和异烟酰胺(INA))的共晶,并开发了这些共晶的油凝胶制剂。本研究首次鉴定了与尿素的共晶和无水 INA 的共晶。通过单晶 X 射线衍射对新的共晶进行了结构表征。溶解度和稳定性研究表明,与母体活性相比,具有 NA 和 INA 的共晶的溶解度更高,并且含有 INA 和尿素的共晶的 FA 在制剂中的稳定性大于含有物理混合物或母体活性的制剂。体外膜渗透试验证实了含有 FA•INA 共晶的制剂中活性的持续释放特征。FA•INA 共晶制剂具有较高的溶解度、更好的稳定性和持续的活性释放特征,使其成为 FA 的一种有前途的局部制剂。